| Association of Genetic Polymorphisms With Capecitabine-based Chemotherapy Toxicities in Chinese Solid Tumor Patients (NCT03258099) | Cui Yimin | 2017-12-28 |
| Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers (NCT03139370) | Kite, A Gilead Company | 2017-12-27 |
| Phase 1 Study Evaluating VT1021 in Patients With Advanced Solid Tumors (NCT03364400) | Vigeo Therapeutics, Inc. | 2017-11-28 |
| Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas (NCT03311412) | Symphogen A/S | 2017-11-20 |
| A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors (NCT03343613) | Eli Lilly and Company | 2017-11-17 |
| Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 (NCT03307785) | Tesaro, Inc. | 2017-10-12 |
| Pharmacokinetics and Tolerancebility Studies of Gentuximab Injection in the Treatment ofPatients With Late Recurrence of Metastatic Solid Tumors in China (NCT03313219) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2017-10-11 |
| A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors (NCT03129139) | Minneamrita Therapeutics LLC | 2017-10-10 |
| Comparison of Three Tissue Acquiring Techniques During EUS Guided Biopsies of Solid Tumors. (NCT03264092) | Texas Tech University Health Sciences Center, El Paso | 2017-09-11 |
| Randomized Controlled Trial of Integrated Early Palliative Care (NCT03181854) | Seoul National University Hospital | 2017-09-08 |
| A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors (NCT03238027) | Syndax Pharmaceuticals | 2017-09-01 |
| PEN-866 in Patients With Advanced Solid Malignancies (NCT03221400) | Tarveda Therapeutics | 2017-08-29 |
| LZM009 to Treat Patients With Advanced Solid Tumors (NCT03286296) | Livzon Pharmaceutical Group Inc. | 2017-08-21 |
| Study of E7389 Liposomal Formulation in Participants With Solid Tumor (NCT03207672) | Eisai Co., Ltd. | 2017-08-18 |
| Biological Effects of Agent on PAR-4 Levels With Resected Solid Tumors (NCT03015324) | Peng Wang, MD PhD | 2017-08-08 |
| The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors (NCT03182673) | Jiangsu HengRui Medicine Co., Ltd. | 2017-07-24 |
| Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors (NCT03182257) | Ono Pharmaceutical Co., Ltd. | 2017-07-12 |
| Dose-Escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma (NCT03168061) | NanoCarrier Co., Ltd. | 2017-06-30 |
| ACTolog in Patients With Solid Cancers (NCT02876510) | Immatics US, Inc. | 2017-06-30 |
| NLG802 Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors (NCT03164603) | NewLink Genetics Corporation | 2017-06-29 |
| Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. (NCT03229200) | Pharmacyclics Switzerland GmbH | 2017-05-22 |
| Expansion Study to Evaluate the Efficacy and Safety of HM95573 in BRAF, KRAS or NRAS Mutant Solid Cancers (NCT03118817) | Hanmi Pharmaceutical Company Limited | 2017-05-19 |
| A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723) (NCT03085914) | Incyte Corporation | 2017-05-02 |
| A DRF Study to Evaluate Safety, Tolerability, PK, and Activity of Oradoxel Monotherapy in Subjects w Adv. Malignancies (NCT02963168) | Athenex, Inc. | 2017-04-20 |
| To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors (NCT03159585) | Zhujiang Hospital | 2017-04-14 |
| A Randomized Prospective Comparison of the New EUS Guided Acquire TM Needle Biopsy vs EUS Guided Fine Needle Aspiration for Suspected Solid Gastrointestinal Lesions (NCT03109639) | Singapore General Hospital | 2017-04-13 |
| A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors (NCT03099109) | Eli Lilly and Company | 2017-04-12 |
| APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors (NCT03053466) | Apollomics (Australia) Pty. Ltd. | 2017-03-27 |
| HDCRT Plus Pembrolizumab in Advanced Malignancies (NCT02987166) | James Larner, MD | 2017-03-21 |
| Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors (NCT03057145) | Geoffrey Shapiro, MD, PhD | 2017-03-10 |
| Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK (NCT02959619) | Betta Pharmaceuticals Co., Ltd. | 2017-03-06 |
| Shared Health Information System for Febrile Neutropenia (NCT03087227) | Marie-Helene METZGER | 2017-02-22 |
| A Study of APG-1252 in Patients With SCLC or Other Solid Tumors (NCT03080311) | Ascentage Pharma Group Inc. | 2017-02-12 |
| A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer (NCT03027284) | Eli Lilly and Company | 2017-02-03 |
| A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01) (NCT03013218) | ALX Oncology Inc. | 2017-02-03 |
| PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas (NCT03013491) | CytomX Therapeutics | 2017-01-19 |
| Radiomics of Immunotherapeutics Response Evaluation and Prediction (NCT04079283) | Tianjin Medical University Cancer Institute and Hospital | 2017-01-01 |
| A Dose Escalation Study to Assess the Safety and Tolerability of HMPL-453 in Patients With Advanced Solid Malignancies (NCT02966171) | Hutchison Medipharma Limited | 2017-01-01 |
| A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers (NCT02643303) | Ludwig Institute for Cancer Research | 2016-12-28 |
| Food-Effect and Metabolism Study in Healthy Subjects (NCT03062982) | Jiangsu HengRui Medicine Co., Ltd. | 2016-12-21 |
| To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer (NCT03006172) | Genentech, Inc. | 2016-12-13 |
| A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) (NCT02974738) | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2016-12-07 |
| A Study of LY3200882 in Participants With Solid Tumors (NCT02937272) | Eli Lilly and Company | 2016-11-21 |
| Merestinib In Non-Small Cell Lung Cancer And Solid Tumors (NCT02920996) | Dana-Farber Cancer Institute | 2016-11-11 |
| A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors (NCT02784795) | Eli Lilly and Company | 2016-11-04 |
| Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer (NCT02953782) | Gilead Sciences | 2016-11-02 |
| Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib (NCT02986100) | pharmaand GmbH | 2016-11-01 |
| Phase I Study of SHR7390 in Patients With Advanced Solid Tumors (NCT02968485) | Jiangsu HengRui Medicine Co., Ltd. | 2016-11-01 |
| Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed Malignancies (NCT01553071) | South Plains Oncology Consortium | 2016-11-01 |
| A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors (NCT03042910) | Pfizer | 2016-10-13 |
| A Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Tripegfilgrastim in Pediatric Solid Tumor/Lymphoma Patients (NCT02963389) | Dong-A ST Co., Ltd. | 2016-10-04 |
| Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product (NCT02840110) | Cogent Biosciences, Inc. | 2016-10-01 |
| Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment (NCT02932280) | Memorial Sloan Kettering Cancer Center | 2016-10-01 |
| Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma (NCT02909777) | Dana-Farber Cancer Institute | 2016-10-01 |
| Understanding Communication in Healthcare to Achieve Trust (U-CHAT) (NCT02846038) | St. Jude Children's Research Hospital | 2016-09-09 |
| A Study of LY2510924 and Durvalumab in Participants With Solid Tumors (NCT02737072) | Eli Lilly and Company | 2016-09-01 |
| Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) (NCT02624388) | University of Virginia | 2016-08-01 |
| Efficacy and Safety of Synthetic Phosphoethanolamine in Solid Tumor Patients (NCT02950103) | Secretaria de Estado da Saúde | 2016-08-01 |
| KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (NCT02867007) | Kyowa Kirin, Inc. | 2016-08-01 |
| Durvalumab in Pediatric and Adolescent Patients (NCT02793466) | Leo Mascarenhas | 2016-07-01 |
| A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors (NCT02791334) | Eli Lilly and Company | 2016-06-29 |
| A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors (NCT02718911) | Eli Lilly and Company | 2016-06-16 |
| Eribulin and Lenvatinib in Advanced Solid Tumors (NCT02640508) | Virginia G. Kaklamani | 2016-05-01 |
| A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor Subjects (NCT02742935) | Jiangsu HengRui Medicine Co., Ltd. | 2016-04-27 |
| A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors (NCT02715531) | Hoffmann-La Roche | 2016-04-06 |
| A Study to Evaluate the Safety, Tolerability, MTD, PK, and Activity of Oraxol in Subjects w Adv. Malignancies (NCT02730481) | Athenex, Inc. | 2016-03-01 |
| MOSE to Improve the Diagnostic Accuracy During EUS-guided FNA Using a 19-gauge Needle for Solid Lesions (NCT03130140) | Chinese University of Hong Kong | 2016-02-26 |
| Medical Treatment Decision Making Using Adaptive Conjoint Analysis (NCT02608307) | St. Jude Children's Research Hospital | 2016-02-09 |
| BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors (NCT02656849) | Dana-Farber Cancer Institute | 2016-02-01 |
| Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors (NCT02705105) | Kyowa Kirin, Inc. | 2016-02-01 |
| A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors (NCT02663518) | Pfizer | 2016-01-28 |
| A Dose Escalation Study of Radio-labeled Antibody for the Treatment of Advanced Cancer (NCT02454010) | Fujifilm Pharmaceuticals U.S.A., Inc. | 2016-01-01 |
| A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C) (NCT02627274) | Hoffmann-La Roche | 2015-12-07 |
| Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors (NCT02608385) | University of Chicago | 2015-12-01 |
| Bergonie Institut Profiling : Fighting Cancer by Matching Molecular Alterations and Drugs in Early Phase Trials (NCT02534649) | Institut Bergonié | 2015-12-01 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors (NCT02541604) | Hoffmann-La Roche | 2015-11-30 |
| Illness Management and Parental Adjustment to Cancer Treatment (NCT02505165) | Children's Hospital Medical Center, Cincinnati | 2015-11-19 |
| Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+ (NCT02593708) | Michelle Melisko | 2015-11-03 |
| Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations (NCT02352844) | Washington University School of Medicine | 2015-10-07 |
| Study of Intravenous RXDX-107 in Patients With Solid Tumors (NCT02548390) | Hoffmann-La Roche | 2015-09-01 |
| A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors (NCT02653196) | Montefiore Medical Center | 2015-09-01 |
| An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study (NCT02488330) | Hoffmann-La Roche | 2015-08-27 |
| HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid Tumors (NCT02536469) | Bristol-Myers Squibb | 2015-08-01 |
| A Study to Determine the Bioequivalence of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel (NCT04035473) | Athenex, Inc. | 2015-08-01 |
| A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors (NCT02471846) | Genentech, Inc. | 2015-07-28 |
| Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors (NCT02472977) | Bristol-Myers Squibb | 2015-07-13 |
| Study of Regorafenib and Sildenafil for Advanced Solid Tumors (NCT02466802) | Virginia Commonwealth University | 2015-07-01 |
| HCQ on PAR-4 Levels in Patients With Resectable Solid Tumors (NCT02232243) | Peng Wang, MD PhD | 2015-07-01 |
| Umbilical Cord Blood Transplantation From Unrelated Donors (NCT03016806) | University of Rochester | 2015-06-01 |
| Study of Combination Therapy With Mogamulizumab (KW-0761) and Nivolumab (ONO-4538/BMS-936558) in Subjects With Advanced Solid Tumors (NCT02476123) | Kyowa Kirin Co., Ltd. | 2015-06-01 |
| A Study of TBI-1401(HF10) in Patients With Solid Tumors With Superficial Lesions (NCT02428036) | Takara Bio Inc. | 2015-06-01 |
| Psychotherapy Intervention for Latinos With Advanced Cancer (NCT04015609) | Memorial Sloan Kettering Cancer Center | 2015-04-20 |
| Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus (NCT02441543) | Istituto Clinico Humanitas | 2015-04-01 |
| Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid Malignancy (NCT02412462) | Alethia Biotherapeutics | 2015-04-01 |
| A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) (NCT02332668) | Merck Sharp & Dohme LLC | 2015-03-19 |
| A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors (NCT02414516) | Oncolys BioPharma Inc | 2015-03-01 |
| Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) (NCT02393248) | Incyte Corporation | 2015-02-27 |
| Study to Evaluate the Safety and Efficacy of Everolimus, in Subjects With PIK3CA Amplification, PTEN Loss and PIK3CA Mutation Refractory Solid Tumors (NCT02449538) | Samsung Medical Center | 2015-02-01 |
| Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1 (NCT02355535) | Vanquish Oncology, Inc. | 2015-02-01 |
| Metronomic Chemotherapy in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma (NCT02517918) | Institut Bergonié | 2015-02-01 |